Xencor (XNCR) EBITDA (2013 - 2026)
Xencor (XNCR) reported EBITDA of -$130.5 million for Q1 2026, down 175.24% year-over-year from $173.4 million in Q1 2025, and down 1923.03% quarter-over-quarter from -$6.4 million in Q4 2025.
Xencor (XNCR) EBITDA (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of EBITDA data on file, last reported at -$130.5 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$130.5 million, down 175.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$173.0 million (up 16.2% YoY), and the FY2025 annual result was -$89.9 million, up 61.68% from the prior year.
- EBITDA declined to -$130.5 million in Q1 2026 per XNCR's latest filing, from -$6.4 million in the prior quarter.
- Over five years, EBITDA peaked at $18.0 million in Q1 2022 and troughed at -$130.5 million in Q1 2026.
- A 5-year average of -$37.6 million and a median of -$33.7 million in 2022 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA jumped 829.83% in 2022, then plunged 419.39% in 2023.
- A 5-year view of EBITDA shows it stood at -$9.1 million in 2022, then plunged by 164.84% to -$24.1 million in 2023, then plunged by 85.28% to -$44.7 million in 2024, then jumped by 85.59% to -$6.4 million in 2025, then plunged by 1923.03% to -$130.5 million in 2026.
- Business Quant data shows XNCR's EBITDA at -$130.5 million in Q1 2026, -$6.4 million in Q4 2025, and -$5.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -130.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -130.47 Mn |
| Dec 31, 2025 | -6.45 Mn |
| Sep 30, 2025 | -5.13 Mn |
| Jun 30, 2025 | -30.92 Mn |
| Mar 31, 2025 | -47.40 Mn |
| Dec 31, 2024 | -44.74 Mn |
| Sep 30, 2024 | -44.99 Mn |
| Jun 30, 2024 | -69.28 Mn |
| Mar 31, 2024 | -74.89 Mn |
| Dec 31, 2023 | -24.15 Mn |
| Sep 30, 2023 | -23.12 Mn |
| Jun 30, 2023 | -20.19 Mn |
| Mar 31, 2023 | -57.44 Mn |
| Dec 31, 2022 | -9.12 Mn |
| Sep 30, 2022 | -33.69 Mn |
| Jun 30, 2022 | -35.80 Mn |
| Mar 31, 2022 | 17.98 Mn |
| Dec 31, 2021 | 71.63 Mn |
| Sep 30, 2021 | -40.25 Mn |
| Jun 30, 2021 | 52.14 Mn |